Taken together with the lack of statistical correlation between CTAB and PD-L1 assessed by IHC, a widely used biomarker for immunotherapy response, these results suggest that CTAB may describe important additional aspects of the tumor-immune microenvironment not accounted for by traditional immunotherapy treatment selection biomarkers. Here, CD274 is linked to neoplasm.